NCT06047548: A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Sponsor: Eli Lilly and Company. Phase: PHASE3. Conditions: Overweight, Obesity